SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Advaxis, Inc. – ‘10-K’ for 10/31/20 – ‘EX-32.2’

On:  Friday, 1/22/21, at 4:38pm ET   ·   For:  10/31/20   ·   Accession #:  1493152-21-1656   ·   File #:  1-36138

Previous ‘10-K’:  ‘10-K/A’ on 2/28/20 for 10/31/19   ·   Next:  ‘10-K/A’ on 2/26/21 for 10/31/20   ·   Latest:  ‘10-K/A’ on 4/26/24 for 12/31/23   ·   40 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/22/21  Advaxis, Inc.                     10-K       10/31/20   86:5.4M                                   M2 Compliance LLC/FA

Annual Report   —   Form 10-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML    714K 
 2: EX-4.9      Instrument Defining the Rights of Security Holders  HTML     49K 
 3: EX-23.1     Consent of Expert or Counsel                        HTML     24K 
 4: EX-31.1     Certification -- §302 - SOA'02                      HTML     31K 
 5: EX-31.2     Certification -- §302 - SOA'02                      HTML     31K 
 6: EX-32.1     Certification -- §906 - SOA'02                      HTML     25K 
 7: EX-32.2     Certification -- §906 - SOA'02                      HTML     25K 
14: R1          Document and Entity Information                     HTML     59K 
15: R2          Balance Sheets                                      HTML    102K 
16: R3          Balance Sheets (Parenthetical)                      HTML     43K 
17: R4          Statements of Operations                            HTML     72K 
18: R5          Statements of Stockholders' Equity                  HTML     91K 
19: R6          Statement of Cash Flows                             HTML    125K 
20: R7          Nature of Operations and Basis of Presentation      HTML     33K 
21: R8          Summary of Significant Accounting Policies          HTML     64K 
22: R9          Property and Equipment                              HTML     33K 
23: R10         Intangible Assets                                   HTML     35K 
24: R11         Accrued Expenses                                    HTML     29K 
25: R12         Common Stock Purchase Warrants and Warrant          HTML     53K 
                Liability                                                        
26: R13         Share Based Compensation                            HTML     68K 
27: R14         Collaboration and Licensing Agreements              HTML     46K 
28: R15         Commitments and Contingencies                       HTML     29K 
29: R16         Leases                                              HTML     46K 
30: R17         Income Taxes                                        HTML     54K 
31: R18         Stockholders' Equity                                HTML     34K 
32: R19         Fair Value                                          HTML     39K 
33: R20         Employee Benefit Plan                               HTML     28K 
34: R21         Subsequent Events                                   HTML     28K 
35: R22         Summary of Significant Accounting Policies          HTML    110K 
                (Policies)                                                       
36: R23         Summary of Significant Accounting Policies          HTML     29K 
                (Tables)                                                         
37: R24         Property and Equipment (Tables)                     HTML     32K 
38: R25         Intangible Assets (Tables)                          HTML     36K 
39: R26         Accrued Expenses (Tables)                           HTML     29K 
40: R27         Common Stock Purchase Warrants and Warrant          HTML     50K 
                Liability (Tables)                                               
41: R28         Share Based Compensation (Tables)                   HTML     68K 
42: R29         Leases (Tables)                                     HTML     51K 
43: R30         Income Taxes (Tables)                               HTML     52K 
44: R31         Fair Value (Tables)                                 HTML     37K 
45: R32         Nature of Operations and Basis of Presentation      HTML     32K 
                (Details Narrative)                                              
46: R33         Summary of Significant Accounting Policies          HTML     53K 
                (Details Narrative)                                              
47: R34         Summary of Significant Accounting Policies and      HTML     31K 
                Basis of Presentation - Schedule of Anti-dilutive                
                Securities Excluded from Diluted Net Loss Per                    
                Share (Details)                                                  
48: R35         Property and Equipment (Details Narrative)          HTML     31K 
49: R36         Property and Equipment - Schedule of Property and   HTML     43K 
                Equipment (Details)                                              
50: R37         Intangible Assets (Details Narrative)               HTML     31K 
51: R38         Intangible Assets - Summary of Intangible Assets    HTML     37K 
                (Details)                                                        
52: R39         Intangible Assets - Schedule of Carrying Value of   HTML     40K 
                Intangible Assets (Details)                                      
53: R40         Accrued Expenses - Components of Accrued Expenses   HTML     34K 
                (Details)                                                        
54: R41         Common Stock Purchase Warrants and Warrant          HTML     93K 
                Liability (Details Narrative)                                    
55: R42         Common Stock Purchase Warrants and Warrant          HTML     42K 
                Liability - Schedule of Outstanding Warrants                     
                (Details)                                                        
56: R43         Common Stock Purchase Warrants and Warrant          HTML     57K 
                Liability - Schedule of Warrants Activity                        
                (Details)                                                        
57: R44         Common Stock Purchase Warrants and Warrant          HTML     29K 
                Liability - Schedule of Warrants Activity                        
                (Details) (Parenthetical)                                        
58: R45         Common Stock Purchase Warrants and Warrant          HTML     50K 
                Liability - Schedule of Assumptions Used in                      
                Warrant Liability (Details)                                      
59: R46         Share Based Compensation (Details Narrative)        HTML     84K 
60: R47         Share Based Compensation - Summary of Share Based   HTML     28K 
                Compensation Expense (Details)                                   
61: R48         Share Based Compensation - Summary of RSU Activity  HTML     39K 
                and Related Information (Details)                                
62: R49         Share Based Compensation - Summary of Changes in    HTML     56K 
                Stock Option Plan (Details)                                      
63: R50         Share Based Compensation - Summary of Outstanding   HTML     70K 
                and Exercisable Options (Details)                                
64: R51         Share Based Compensation - Summary of Fair Value    HTML     36K 
                of Stock Options Granted of BSM (Details)                        
65: R52         Collaboration and Licensing Agreements (Details     HTML     86K 
                Narrative)                                                       
66: R53         Commitments and Contingencies (Details Narrative)   HTML     31K 
67: R54         Leases (Details Narrative)                          HTML     29K 
68: R55         Leases - Schedule of Supplemental Balance Sheet     HTML     32K 
                Related to Leases (Details)                                      
69: R56         Leases - Schedule of Lease Expenses (Details)       HTML     32K 
70: R57         Leases - Schedule of Other Information Related to   HTML     29K 
                Leases (Details)                                                 
71: R58         Leases - Schedule of Cash Flow Information Related  HTML     26K 
                to Leases (Details)                                              
72: R59         Leases - Schedule of Future Minimum Lease Payments  HTML     43K 
                Under Non-Cancellable Leases (Details)                           
73: R60         Leases - Schedule of Future Minimum Payments Under  HTML     42K 
                Operating Lease (Details)                                        
74: R61         Income Taxes (Details Narrative)                    HTML     44K 
75: R62         Income Taxes - Schedule of Income Tax Provision     HTML     39K 
                (Benefit) (Details)                                              
76: R63         Income Taxes - Schedule of Deferred Tax Assets      HTML     58K 
                (Liabilities) (Details)                                          
77: R64         Income Taxes - Schedule of Expected Tax (Expense)   HTML     43K 
                Benefit Based on Statutory Rate with Actual Tax                  
                Expense Benefit (Details)                                        
78: R65         Stockholders' Equity (Details Narrative)            HTML     90K 
79: R66         Fair Value - Schedule of Fair Value, Assets and     HTML     30K 
                Liabilities Measured on Recurring Basis (Details)                
80: R67         Fair Value - Schedule of Fair Value, Assets and     HTML     26K 
                Liabilities Measured on Recurring Basis (Details)                
                (Parenthetical)                                                  
81: R68         Fair Value - Schedule of Changes in Fair Value of   HTML     33K 
                Warrant Liabilities (Details)                                    
82: R69         Employee Benefit Plan (Details Narrative)           HTML     26K 
83: R70         Subsequent Events (Details Narrative)               HTML     67K 
85: XML         IDEA XML File -- Filing Summary                      XML    155K 
84: EXCEL       IDEA Workbook of Financial Reports                  XLSX    108K 
 8: EX-101.INS  XBRL Instance -- adxs-20201031                       XML   1.29M 
10: EX-101.CAL  XBRL Calculations -- adxs-20201031_cal               XML    230K 
11: EX-101.DEF  XBRL Definitions -- adxs-20201031_def                XML    526K 
12: EX-101.LAB  XBRL Labels -- adxs-20201031_lab                     XML   1.13M 
13: EX-101.PRE  XBRL Presentations -- adxs-20201031_pre              XML    858K 
 9: EX-101.SCH  XBRL Schema -- adxs-20201031                         XSD    189K 
86: ZIP         XBRL Zipped Folder -- 0001493152-21-001656-xbrl      Zip    148K 


‘EX-32.2’   —   Certification — §906 – SOA’02


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 

EXHIBIT 32.2

 

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of Advaxis, Inc., a Delaware corporation (the “Company”), on Form 10-K for the fiscal year ended October 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, the Chief Financial Officer, hereby certifies pursuant to 18 U.S.C. Sec. 1350 as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002 that, to the undersigned’s knowledge:

 

(1) the Report of the Company filed today fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

 

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

Date: January 22, 2021 By: /s/ Kenneth Berlin
  Name:  Kenneth Berlin
  Title: President, Chief Executive Officer and interim Chief Financial Officer

 

 C: 
 


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
Filed on:1/22/21
For Period end:10/31/2010-K/A
 List all Filings 


40 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/27/20  Ayala Pharmaceuticals, Inc.       8-K:1,8,9  11/24/20    5:504K                                   M2 Compliance LLC/FA
 9/29/20  Ayala Pharmaceuticals, Inc.       8-K:1,3,5,8 9/29/20    5:784K                                   M2 Compliance LLC/FA
 8/03/20  Ayala Pharmaceuticals, Inc.       8-K:1,7,9   7/30/20    5:437K                                   M2 Compliance LLC/FA
 5/08/20  Ayala Pharmaceuticals, Inc.       8-K:1,9     5/08/20    3:345K                                   M2 Compliance LLC/FA
 3/20/20  Ayala Pharmaceuticals, Inc.       DEF 14A     3/20/20    1:941K                                   M2 Compliance LLC/FA
 1/23/20  Ayala Pharmaceuticals, Inc.       8-K:1,3,8,9 1/21/20    6:576K                                   M2 Compliance LLC/FA
 9/11/18  Ayala Pharmaceuticals, Inc.       8-K:1,8,9   9/06/18    7:814K                                   M2 Compliance LLC/FA
 6/06/18  Ayala Pharmaceuticals, Inc.       8-K:5,9     6/06/18    2:146K                                   M2 Compliance LLC/FA
 3/21/18  Ayala Pharmaceuticals, Inc.       8-K:5,9     3/21/18    2:53K                                    M2 Compliance LLC/FA
 2/06/18  Ayala Pharmaceuticals, Inc.       DEF 14A     2/06/18    1:1.2M                                   M2 Compliance LLC/FA
 7/07/17  Ayala Pharmaceuticals, Inc.       8-K:5,9     7/06/17    2:86K                                    M2 Compliance LLC/FA
 2/10/17  Ayala Pharmaceuticals, Inc.       DEF 14A     2/10/17    1:1.2M                                   M2 Compliance LLC/FA
 3/11/16  Ayala Pharmaceuticals, Inc.       8-K:5,9     3/10/16    2:63K                                    M2 Compliance LLC/FA
 2/26/16  Ayala Pharmaceuticals, Inc.       10-Q        1/31/16   67:3.5M                                   M2 Compliance LLC/FA
 2/11/16  Ayala Pharmaceuticals, Inc.       DEF 14A     2/11/16    1:1.1M                                   M2 Compliance LLC/FA
 6/15/15  Ayala Pharmaceuticals, Inc.       10-Q        4/30/15   70:3.7M                                   M2 Compliance LLC/FA
 4/07/15  Ayala Pharmaceuticals, Inc.       DEF 14A     4/07/15    1:1.9M                                   M2 Compliance LLC/FA
 1/06/15  Ayala Pharmaceuticals, Inc.       10-K       10/31/14   77:8.9M                                   M2 Compliance LLC/FA
 9/09/14  Ayala Pharmaceuticals, Inc.       10-Q        7/31/14   68:4.2M                                   M2 Compliance LLC/FA
 7/10/14  Ayala Pharmaceuticals, Inc.       8-K:5,9     7/09/14    3:129K                                   M2 Compliance LLC/FA
 6/10/14  Ayala Pharmaceuticals, Inc.       10-Q        4/30/14   75:4.8M                                   M2 Compliance LLC/FA
 5/20/14  Ayala Pharmaceuticals, Inc.       DEFR14A     5/20/14    1:1.2M                                   M2 Compliance LLC/FA
 3/17/14  Ayala Pharmaceuticals, Inc.       10-Q        1/31/14   67:5.4M                                   Toppan Merrill/FA
 2/11/14  Ayala Pharmaceuticals, Inc.       8-K:1,9     2/05/14    3:398K                                   Toppan Merrill/FA
 2/06/14  Ayala Pharmaceuticals, Inc.       10-K/A     10/31/13    7:548K                                   Toppan Merrill/FA
 9/27/13  Advaxis, Inc.                     S-1/A                 10:5.8M                                   Toppan Merrill/FA
 8/20/13  Advaxis, Inc.                     8-K:5,8,9   8/14/13    5:297K                                   Toppan Merrill/FA
 7/15/13  Advaxis, Inc.                     8-K:8,9     7/11/13    4:520K                                   Toppan Merrill/FA
 8/17/12  Advaxis, Inc.                     8-K:5,9     8/13/12    2:48K                                    Toppan Merrill/FA
 7/19/12  Advaxis, Inc.                     DEF 14A     8/13/12    1:992K                                   Toppan Merrill/FA
 6/14/12  Advaxis, Inc.                     10-Q        4/30/12   40:2.5M                                   Toppan Merrill/FA
 8/31/11  Advaxis, Inc.                     8-K:1,3,9   8/29/11    3:235K                                   Toppan Merrill/FA
 8/29/11  Advaxis, Inc.                     DEF 14A     9/27/11    1:1.5M                                   Toppan Merrill/FA
 7/20/10  Advaxis, Inc.                     8-K:1,3,5,8 7/19/10    4:682K                                   Toppan Merrill/FA
 6/03/10  Advaxis, Inc.                     10-Q        4/30/10    6:1M                                     Toppan Merrill/FA
 4/30/10  Advaxis, Inc.                     DEF 14A     6/01/10    1:859K                                   Toppan Merrill/FA
 9/25/09  Advaxis, Inc.                     8-K:1,3,5,8 9/24/09    4:571K                                   Toppan Merrill/FA
10/23/07  Advaxis, Inc.                     8-K:1,3,9  10/17/07   11:57M                                    Toppan Merrill/FA
 2/13/07  Advaxis, Inc.                     10KSB      10/31/06   11:3.5M                                   Toppan Merrill/FA
 5/15/06  Advaxis, Inc.                     DEF 14A     6/06/06    1:307K                                   Toppan Merrill/FA
Top
Filing Submission 0001493152-21-001656   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., May 10, 7:19:39.3am ET